FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317388421> ?p ?o ?g. }

• W4317388421 abstract "Background: The clinical applications of stromal vascular fraction (SVF) therapy for osteoarthritis (OA) have attracted academic and clinical attention. However, data of the effects of stromal vascular fraction therapy on regeneration of degenerated cartilage are limited in the literature. Meanwhile, there is a great need for a simple and non-invasive evaluation method to analyze the changes of joint cartilage qualitatively and quantitatively in clinical trials. This study entitled “stromal vascular fraction Therapy for Human Knee Osteoarthritis” was registered in ClinicalTrial.gov # NCT05019378. Materials and Methods: We designed and conducted a single center, open labeled clinical phase I/II study, and 6 osteoarthritis patients with both knee cartilage defect I-II were enrolled in this study. The two knees of each patient were randomly assigned to autologous stromal vascular fraction treatment group or non-treatment control group to evaluate the safety and therapeutic effect of stromal vascular fraction therapy for human knee osteoarthritis. We have also established a novel protocol to provide 3D MRI imaging for human knee cartilage enabling us to qualitatively and quantitatively evaluate cartilage degeneration and regeneration in this study. Results: The qualitative and quantitative evaluation of 3D Magnetic Resonance Imaging (MRI) imaging of knee cartilage demonstrated that the stromal vascular fraction therapy reduced the cartilage defects; and significant increase of cartilage value both in defect cartilage area and whole cartilage area of treated group and significant increase of thickness and area of both femoral and tibia cartilage in vertical sections of the stromal vascular fraction treated Group at 12 and 24 W post treatment in cartilage defect I-II osteoarthritis patients. Conclusion: This clinical phase I/II study indicated that stromal vascular fraction therapy is a safe clinical procedure and provided evidence that the stromal vascular fraction therapy significantly facilitated cartilage regeneration, opening the opportunity to a phase III trial investigating authentic efficacy of the procedure. This study is the first qualitative and quantitative evaluation of the efficacy of autologous stromal vascular fraction cellular therapy on cartilage regeneration. Through early and definite diagnosis of knee osteoarthritis patients, and providing safe and efficient therapy to facilitate cartilage regeneration, we will be able to control or reverse cartilage degeneration and completely change the epidemiology of osteoarthritis worldwide." @default.
• W4317388421 created "2023-01-19" @default.
• W4317388421 creator A5003260015 @default.
• W4317388421 creator A5018582393 @default.
• W4317388421 creator A5027803461 @default.
• W4317388421 creator A5048064996 @default.
• W4317388421 creator A5049444769 @default.
• W4317388421 creator A5061607174 @default.
• W4317388421 creator A5065981642 @default.
• W4317388421 creator A5067544146 @default.
• W4317388421 creator A5069147685 @default.
• W4317388421 creator A5071584579 @default.
• W4317388421 creator A5071778912 @default.
• W4317388421 creator A5077088242 @default.
• W4317388421 creator A5078143614 @default.
• W4317388421 creator A5079813186 @default.
• W4317388421 creator A5083848205 @default.
• W4317388421 creator A5086326013 @default.
• W4317388421 creator A5090356260 @default.
• W4317388421 date "2023-01-19" @default.
• W4317388421 modified "2023-10-01" @default.
• W4317388421 title "Clinical phase I/II trial of SVF therapy for cartilage regeneration: A cellular therapy with novel 3D MRI imaging for evaluating chondral defect of knee osteoarthritis" @default.
• W4317388421 cites W1958303027 @default.
• W4317388421 cites W1980718328 @default.
• W4317388421 cites W1983616143 @default.
• W4317388421 cites W1983766143 @default.
• W4317388421 cites W1999350636 @default.
• W4317388421 cites W2011170585 @default.
• W4317388421 cites W2011171855 @default.
• W4317388421 cites W2028046200 @default.
• W4317388421 cites W2028089243 @default.
• W4317388421 cites W2030594039 @default.
• W4317388421 cites W2083156208 @default.
• W4317388421 cites W2090291483 @default.
• W4317388421 cites W2118788475 @default.
• W4317388421 cites W2139826506 @default.
• W4317388421 cites W2161096568 @default.
• W4317388421 cites W2224501223 @default.
• W4317388421 cites W2267939095 @default.
• W4317388421 cites W2291567144 @default.
• W4317388421 cites W2332843880 @default.
• W4317388421 cites W2397516852 @default.
• W4317388421 cites W2500482172 @default.
• W4317388421 cites W2511470349 @default.
• W4317388421 cites W2525605182 @default.
• W4317388421 cites W2552219167 @default.
• W4317388421 cites W2598337322 @default.
• W4317388421 cites W2625285338 @default.
• W4317388421 cites W2762130295 @default.
• W4317388421 cites W2785969335 @default.
• W4317388421 cites W2929526016 @default.
• W4317388421 cites W2947561084 @default.
• W4317388421 cites W2990758172 @default.
• W4317388421 cites W2991459327 @default.
• W4317388421 cites W4242496684 @default.
• W4317388421 doi "https://doi.org/10.3389/fcell.2023.1106279" @default.
• W4317388421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36743417" @default.
• W4317388421 hasPublicationYear "2023" @default.
• W4317388421 type Work @default.
• W4317388421 citedByCount "0" @default.
• W4317388421 crossrefType "journal-article" @default.
• W4317388421 hasAuthorship W4317388421A5003260015 @default.
• W4317388421 hasAuthorship W4317388421A5018582393 @default.
• W4317388421 hasAuthorship W4317388421A5027803461 @default.
• W4317388421 hasAuthorship W4317388421A5048064996 @default.
• W4317388421 hasAuthorship W4317388421A5049444769 @default.
• W4317388421 hasAuthorship W4317388421A5061607174 @default.
• W4317388421 hasAuthorship W4317388421A5065981642 @default.
• W4317388421 hasAuthorship W4317388421A5067544146 @default.
• W4317388421 hasAuthorship W4317388421A5069147685 @default.
• W4317388421 hasAuthorship W4317388421A5071584579 @default.
• W4317388421 hasAuthorship W4317388421A5071778912 @default.
• W4317388421 hasAuthorship W4317388421A5077088242 @default.
• W4317388421 hasAuthorship W4317388421A5078143614 @default.
• W4317388421 hasAuthorship W4317388421A5079813186 @default.
• W4317388421 hasAuthorship W4317388421A5083848205 @default.
• W4317388421 hasAuthorship W4317388421A5086326013 @default.
• W4317388421 hasAuthorship W4317388421A5090356260 @default.
• W4317388421 hasBestOaLocation W43173884211 @default.
• W4317388421 hasConcept C105702510 @default.
• W4317388421 hasConcept C126838900 @default.
• W4317388421 hasConcept C141071460 @default.
• W4317388421 hasConcept C142724271 @default.
• W4317388421 hasConcept C143409427 @default.
• W4317388421 hasConcept C16930146 @default.
• W4317388421 hasConcept C204787440 @default.
• W4317388421 hasConcept C2776164576 @default.
• W4317388421 hasConcept C2780550940 @default.
• W4317388421 hasConcept C2780745355 @default.
• W4317388421 hasConcept C2908736133 @default.
• W4317388421 hasConcept C71924100 @default.
• W4317388421 hasConceptScore W4317388421C105702510 @default.
• W4317388421 hasConceptScore W4317388421C126838900 @default.
• W4317388421 hasConceptScore W4317388421C141071460 @default.
• W4317388421 hasConceptScore W4317388421C142724271 @default.
• W4317388421 hasConceptScore W4317388421C143409427 @default.
• W4317388421 hasConceptScore W4317388421C16930146 @default.
• W4317388421 hasConceptScore W4317388421C204787440 @default.
• W4317388421 hasConceptScore W4317388421C2776164576 @default.
• W4317388421 hasConceptScore W4317388421C2780550940 @default.

• next